vs

Side-by-side financial comparison of ALT5 Sigma Corp (ALTS) and Baird Medical Investment Holdings Ltd (BDMD). Click either name above to swap in a different company.

Baird Medical Investment Holdings Ltd is the larger business by last-quarter revenue ($8.0M vs $5.4M, roughly 1.5× ALT5 Sigma Corp). Baird Medical Investment Holdings Ltd runs the higher net margin — -142.7% vs -7100.2%, a 6957.5% gap on every dollar of revenue. Baird Medical Investment Holdings Ltd produced more free cash flow last quarter ($-3.2M vs $-7.2M).

ALT5 Sigma Corp is a fintech firm focused on digital asset infrastructure and trading solutions. It operates regulated digital asset trading platforms for retail and institutional clients, primarily serving markets across North America, Europe, and the Asia-Pacific region. Its core offerings include spot and derivatives trading, digital asset custody, and secure settlement services.

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

ALTS vs BDMD — Head-to-Head

Bigger by revenue
BDMD
BDMD
1.5× larger
BDMD
$8.0M
$5.4M
ALTS
Higher net margin
BDMD
BDMD
6957.5% more per $
BDMD
-142.7%
-7100.2%
ALTS
More free cash flow
BDMD
BDMD
$3.9M more FCF
BDMD
$-3.2M
$-7.2M
ALTS

Income Statement — Q4 FY2025 vs Q2 FY2025

Metric
ALTS
ALTS
BDMD
BDMD
Revenue
$5.4M
$8.0M
Net Profit
$-381.5M
$-11.4M
Gross Margin
40.9%
82.1%
Operating Margin
-38.1%
-131.3%
Net Margin
-7100.2%
-142.7%
Revenue YoY
12.5%
Net Profit YoY
-7249.1%
EPS (diluted)
$-5.53

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALTS
ALTS
BDMD
BDMD
Q4 25
$5.4M
Q3 25
$7.6M
Q2 25
$6.4M
$8.0M
Q1 25
$5.5M
Q4 24
$4.8M
Q3 24
$4.9M
Q2 24
$2.2M
Q1 24
$0
Net Profit
ALTS
ALTS
BDMD
BDMD
Q4 25
$-381.5M
Q3 25
$49.0M
Q2 25
$-9.1M
$-11.4M
Q1 25
$-2.9M
Q4 24
$-5.2M
Q3 24
$-822.0K
Q2 24
$589.0K
Q1 24
$-2.1M
Gross Margin
ALTS
ALTS
BDMD
BDMD
Q4 25
40.9%
Q3 25
34.6%
Q2 25
43.5%
82.1%
Q1 25
47.0%
Q4 24
45.8%
Q3 24
47.8%
Q2 24
50.6%
Q1 24
Operating Margin
ALTS
ALTS
BDMD
BDMD
Q4 25
-38.1%
Q3 25
-218.3%
Q2 25
-32.8%
-131.3%
Q1 25
-39.4%
Q4 24
-40.8%
Q3 24
-14.8%
Q2 24
-112.2%
Q1 24
Net Margin
ALTS
ALTS
BDMD
BDMD
Q4 25
-7100.2%
Q3 25
646.4%
Q2 25
-142.9%
-142.7%
Q1 25
-51.9%
Q4 24
-108.7%
Q3 24
-16.6%
Q2 24
27.2%
Q1 24
EPS (diluted)
ALTS
ALTS
BDMD
BDMD
Q4 25
$-5.53
Q3 25
$0.29
Q2 25
$-0.49
Q1 25
$-0.18
Q4 24
$-0.35
Q3 24
$-0.06
Q2 24
$0.07
Q1 24
$-0.34

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALTS
ALTS
BDMD
BDMD
Cash + ST InvestmentsLiquidity on hand
$6.2M
Total DebtLower is stronger
$563.0K
$8.4M
Stockholders' EquityBook value
$1.2B
$35.6M
Total Assets
$1.2B
$77.0M
Debt / EquityLower = less leverage
0.00×
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALTS
ALTS
BDMD
BDMD
Q4 25
$6.2M
Q3 25
$7.3M
Q2 25
$9.6M
Q1 25
$10.8M
Q4 24
$7.2M
Q3 24
$8.7M
Q2 24
$5.8M
Q1 24
$61.0K
Total Debt
ALTS
ALTS
BDMD
BDMD
Q4 25
$563.0K
Q3 25
Q2 25
$8.4M
Q1 25
Q4 24
$563.0K
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ALTS
ALTS
BDMD
BDMD
Q4 25
$1.2B
Q3 25
$1.6B
Q2 25
$26.1M
$35.6M
Q1 25
$21.8M
Q4 24
$12.4M
Q3 24
$20.2M
Q2 24
$22.9M
Q1 24
$3.8M
Total Assets
ALTS
ALTS
BDMD
BDMD
Q4 25
$1.2B
Q3 25
$1.6B
Q2 25
$94.7M
$77.0M
Q1 25
$78.0M
Q4 24
$75.7M
Q3 24
$74.9M
Q2 24
$75.4M
Q1 24
$18.6M
Debt / Equity
ALTS
ALTS
BDMD
BDMD
Q4 25
0.00×
Q3 25
Q2 25
0.24×
Q1 25
Q4 24
0.05×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALTS
ALTS
BDMD
BDMD
Operating Cash FlowLast quarter
$-7.2M
$-3.2M
Free Cash FlowOCF − Capex
$-7.2M
$-3.2M
FCF MarginFCF / Revenue
-133.4%
-40.7%
Capex IntensityCapex / Revenue
0.2%
0.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALTS
ALTS
BDMD
BDMD
Q4 25
$-7.2M
Q3 25
$-8.7M
Q2 25
$-5.2M
$-3.2M
Q1 25
$-1.5M
Q4 24
$1.8M
Q3 24
$4.2M
Q2 24
$80.0K
Q1 24
$-544.0K
Free Cash Flow
ALTS
ALTS
BDMD
BDMD
Q4 25
$-7.2M
Q3 25
Q2 25
$-3.2M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
ALTS
ALTS
BDMD
BDMD
Q4 25
-133.4%
Q3 25
Q2 25
-40.7%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
ALTS
ALTS
BDMD
BDMD
Q4 25
0.2%
Q3 25
Q2 25
0.6%
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Cash Conversion
ALTS
ALTS
BDMD
BDMD
Q4 25
Q3 25
-0.18×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.14×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons